Asynchronous prescribing by state: where a questionnaire visit is enough

The economics of a direct-to-consumer clinic rest on one assumption: that a clinician can review a completed intake and write a prescription without a scheduled appointment. That assumption holds in most states for most non-controlled medications. It fails in some states, it fails everywhere for controlled substances, and it fails in specific ways that an operator has to design around before the first ad runs. This post lays out how asynchronous telehealth prescribing works across the states as a set of patterns and describes the intake design that survives all of them. A fifty-state table goes stale within a legislative session; the state index carries the per-state detail.

What asynchronous legally means

Asynchronous, or store-and-forward, describes a visit in which the patient's information is collected at one time and reviewed by the clinician at another, with no real-time interaction between them. California's telehealth statute, Business and Professions Code section 2290.5, defines it as "the transmission of a patient's medical information from an originating site to the health care provider at a distant site," and defines the synchronous alternative as "a real-time interaction between a patient and a health care provider located at a distant site." Most state definitions follow the same split. A questionnaire visit is the common form of asynchronous care in a consumer clinic: the patient answers a structured medical history, uploads photos or records where the treatment calls for them, and a licensed clinician reviews the file, asks follow-up questions through secure messaging if needed, and prescribes or declines.

Two legal questions sit underneath every async prescription. The first is whether the encounter establishes a valid patient-provider relationship under the state's rules, because in most states a prescription without one is not a valid prescription. The second is whether the encounter meets the standard of care for that treatment, which is a clinical question the board judges after the fact. Most states answer the first question in statute and leave the second to the clinician, so "async is legal here" is never the whole answer: async can be a lawful way to form the relationship and still fall below the standard of care for a particular drug or patient.

The federal floor for controlled substances

Federal law sets a floor that no state can lower. The Ryan Haight Act, the 2008 amendment to the Controlled Substances Act, requires at least one in-person medical evaluation before a practitioner may prescribe a controlled substance over the internet, unless the practitioner falls within one of the statute's telemedicine exceptions. The statute's definition of telemedicine is built on a real-time, interactive audio-video system. A stored questionnaire, on its own, is not telemedicine for this purpose, so a questionnaire-only encounter has never been a lawful basis for a controlled-substance prescription to a new patient under federal law, whatever the state says.

The in-person requirement itself has been suspended since the pandemic. The DEA and HHS have extended the telemedicine flexibilities four times; the fourth extension, published in the Federal Register on December 31, 2025, runs from January 1 through December 31, 2026. Under the flexibilities a practitioner may prescribe a controlled substance to a patient never seen in person, provided the evaluation is conducted by a live audio-video visit, or in defined cases by audio, and the other conditions of the notice are met. In January 2025 the DEA proposed a permanent special-registration rule for telemedicine prescribing. As of this writing the flexibilities are the operative rule; trade press reports that a final rule may land before the flexibilities expire, and an operator prescribing controlled substances should plan for either outcome rather than assume a fifth extension.

Any treatment that involves a controlled substance runs on a live-visit path, with the encounter documented as such and the prescription sent through a certified EPCS system. Everything below is about non-controlled medications.

How states split: questionnaire allowed, live visit required, in-person first

For non-controlled drugs, state rules fall into three patterns. In the first and largest group, the state recognizes store-and-forward as a valid way to establish the relationship, and the only remaining constraint is the standard of care. The statute or board rule typically says the relationship may be formed by any telehealth modality that allows the practitioner to meet the standard of care, or lists store-and-forward alongside audio-video. An async intake for a low-risk medication is lawful in these states if the clinician has enough information to prescribe safely.

In the second group, the state requires a real-time encounter to establish a new relationship. Some of these states require audio-video; some accept audio-only; several allow async once the relationship exists, so that renewals and follow-ups can run on questionnaires even when the first visit could not. The group is small, but it has at various times included large patient markets, and an operator whose funnel assumes async everywhere finds out about them from a board letter.

In the third group, an in-person examination is required before certain prescriptions. For general non-controlled prescribing this is now rare; it survives mainly for specific drug classes and in professions other than medicine where the prescribing statute is different. An operator in the verticals this site covers is unlikely to hit a general in-person rule, but may hit one attached to a particular drug.

Texas is a useful worked example of the first pattern written into statute, because it lists the acceptable methods rather than leaving them to the board. Texas Occupations Code section 111.005, in the version current as of January 1, 2026, says a practitioner-patient relationship for telemedicine may be established by a synchronous audiovisual interaction; by asynchronous store-and-forward technology, provided the practitioner uses clinical information from clinically relevant photographic or video images or from the patient's relevant clinical records, which the statute describes as the medical history, laboratory and pathology results and prescriptive history; or by another form of audiovisual technology that allows the practitioner to meet the standard of care. Read closely, the Texas statute does not say a questionnaire is enough or not enough. It says the async path has to rest on clinical records or clinical images. An intake that captures a real medical history in a form the clinician can rely on is a clinical record. A ten-question symptom checklist is not.

States that name the internet questionnaire alone

Many state statutes and board rules contain a sentence to the effect that a prescription may not be issued, or a relationship may not be formed, on the basis of an internet questionnaire alone. Operators read that sentence as a ban on async and it usually is not. It is a ban on a bare questionnaire: a static form, no clinician engagement, no ability to ask for more, no way to decline. The sentence was written against the pill-mill sites of the 2000s and most boards apply it that way.

What separates an async visit from a questionnaire alone, in the reading most boards apply, is the same set of things Texas wrote into its statute. The intake collects a medical history, current medications, allergies, relevant vitals and, where the treatment calls for it, photos or recent labs. A licensed clinician reviews the file rather than an algorithm approving it, can message the patient for more, can escalate to a live visit, and can refuse. The chart records the modality, the information relied on and the reasoning. Where a state's rule uses the questionnaire-alone language and the brand's intake is in substance a questionnaire, the operator has to add something: photos, prior records, labs, or a live touchpoint. The reading of any specific state's rule belongs to counsel licensed there.

A questionnaire that a clinician can act on, question, escalate or refuse is a clinical record. A form that approves itself is the thing the statutes were written against.

What this changes for weight loss, hair, skin and sexual health versus TRT and ADHD

The verticals split cleanly along the controlled-substance line. GLP-1 medications for weight loss, finasteride and minoxidil for hair, tretinoin and other topical prescriptions for skin, and the PDE5 inhibitors for erectile dysfunction are not controlled substances. In the first-pattern states they can be prescribed on an async intake, subject to the standard of care, which for GLP-1s in particular is where clinicians expect baseline information that a symptom form does not supply. The design question in these verticals is what the intake has to collect for the clinician to prescribe safely, and how to route the patient to a live visit when the answers raise a flag.

Testosterone is a Schedule III controlled substance, and the stimulants used for ADHD are Schedule II. Both sit on the federal floor. A TRT brand can and should use an async intake to collect history, symptoms and lab orders, because that work does not have to happen live, but the prescribing encounter must be a real-time audio-video visit under the current flexibilities, and the prescription must go through EPCS. Several states add their own conditions to controlled-substance telemedicine on top of the federal rule, including limits by schedule and in some cases prescription-monitoring checks before each script. An ADHD program carries the same requirements with a Schedule II drug, tighter refill rules and, since 2023, a level of scrutiny from the DEA that has ended more than one telehealth company. For these verticals the live visit is the product, and the async intake exists to make the live visit shorter.

What a forced live visit does to cost and conversion

A live visit changes the shape of the funnel more than its length. In an async model the patient completes checkout and the clinician reviews the file within hours, in a batch, at a time of the clinician's choosing. A live visit inserts a scheduling step between checkout and prescription. The patient has to pick a slot, show up, and be reachable on video; the clinician has to be licensed in that patient's state and free at that time. Every one of those steps is a place where a paying patient drops.

On the cost side, the clinician minute is the unit that matters. A synchronous visit occupies a fixed block on a calendar whether or not the patient is straightforward; an async review takes the time the file needs. Provider capacity, which in an async model is a pool, becomes a schedule, and capacity per state licence becomes the constraint. Brands that expect to run live visits in a share of their states should price the provider cost per completed visit rather than per month. Tessic Health charges a flat $25 per completed consult on either path, which keeps the unit cost of a live-visit state the same as an async state; what changes is the conversion rate, and that is the number to model.

Building a two-path intake

An async-first brand does not need two products. It needs one intake with a routing decision in the middle. The pieces that make it work:

• Establish the patient's state from where the patient will be at the time of the visit, confirmed by the patient, rather than from the billing address or the IP.
• Keep a rules table with three inputs, state, treatment and patient status (new or established), and one output: async review, live audio-video visit, or audio-only where the state allows it. Controlled substances route to the live path in every state without exception.
• Collect on the async path everything a clinician needs to treat the file as a clinical record: history, medications, allergies, relevant vitals, photos where the treatment calls for them, and lab orders where the protocol requires baseline results.
• Give the clinician a one-click escalation from async to live, so that an ambiguous file becomes a scheduled visit instead of a decline.
• Get consent for the modality before the questionnaire, since several states require the patient to be told that store-and-forward is being used and to agree to it.
• Record the modality on every encounter, because a board reviewing a chart two years later will ask which path was used and why.
• Report conversion by path and by state, so a state that converts poorly on the live path can be priced or paused on evidence.

Built this way, a change in a state's rule is a row in the table rather than a rebuild. When a state moves from questionnaire-allowed to live-visit-required, new patients in that state go to a scheduler and nothing else changes. When the federal flexibilities expire or a final DEA rule replaces them, the controlled-substance row updates.

The store-and-forward path and the live path both need a licensed provider in the patient's state at the moment of the visit. Tessic Health's clinical network covers all fifty states across physicians and nurse practitioners, its intake routes each patient by state and treatment to the async or live path, and the controlled-substance path runs through EPCS as part of the same flow, so that a client brand launches with both paths working on day one and adds states by demand rather than by which rules the brand has learned to handle.

Questions operators ask

Is a phone call enough where a live visit is required? In some states, for some treatments. Audio-only is accepted by some boards as a synchronous encounter and rejected by others, and the federal flexibilities allow audio-only for controlled substances only in defined cases. The rules table needs a separate output for audio-only rather than treating it as a substitute for video everywhere.

Can a follow-up or refill run async in a state that required a live first visit? Often yes. Several live-first states limit the requirement to establishing the relationship, and once it exists the same clinician or practice can manage the patient asynchronously. The rules table needs the new-or-established input for this reason.